voda schreef op 3 juni 2021 08:36:
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Launch of two new PCR COVID-19 assays
Paris, France and Camberley, UK – 3 June 2021 – Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the
launch of two new polymerase chain reaction (PCR) assays, expanding its genesig®
COVID-19 and SNPsig® SARS-CoV-2 variant detection portfolios.
• genesig® COVID-19 3G is a CE-Marked three-gene assay to detect the ORF1ab,
M gene, and S gene targets of SARS-CoV-2, enabling fulfilment of certain
international testing requirements, including Fit to Fly Certificate, Test to Release
and US Food and Drug Administration regulations.
• SNPsig® EscapePLEX SARS-CoV-2 is a first-to-market assay panel in a single kit
able to detect the four most critical SARS-CoV-2 mutations currently recognised,
combined with a confirmatory two-gene assay for COVID-19. The research-useonly kit detects the biologically significant ‘escape’ mutations E484K, K417N, K417T and P681R, present in the Alpha, Beta, Gamma and Delta Variants1 of Concern
(VoC), and also incorporates the two gene (ORF1ab and M) assay to provide a confirmatory detection of SARS-CoV-2.
Novacyt’s genesig® portfolio is a well-established range of PCR kits for pathogen detection.
The new three-gene assay for COVID-19 has been developed in recognition of rapidly
changing testing needs dictated by SARS-CoV-2 mutations and complements the
Company’s existing one-gene, two-gene, and high-throughput tests. The Company aims
to capture a wider share of the growing global travel market for COVID-19 testing with
the three-gene test.
The SNPsig® portfolio is initially focused on detecting the most significant mutations, VoC
and variants of SARS-CoV-2 and currently includes 13 assays. The Company believes the
SNPsig® EscapePLEX SARS-CoV-2 will be crucial in helping clinicians and public healthcare
centres globally identify SARS-CoV-2 mutations which can impact transmissibility,
immunity, and infection severity2
.
Graham Mullis, Chief Executive Officer of Novacyt, commented:
“The success of our COVID-19 PCR assays has been built around robust design principles
and our real-time bioinformatics surveillance programme to monitor new SARS-CoV-2
genome sequences. As a result, our genesig® COVID-19 portfolio is highly accurate despite
mutations, and we believe our SNPsig® portfolio is the world’s largest for detecting SARSCoV-2 variants. The addition of both of these new assays ensures that Novacyt’s COVID
1
www.who.int/en/activities/tracking-SA...2
www.ecdc.europa.eu/en/covid-19/varian...19 solutions remain robust and that pragmatic options are available to support both public
health and private sector testing alike.”
End
novacyt.com/wp-content/uploads/2021/0...(er is nog meer, zie link)